• China’s NMPA cleared an IND to start mainland China trials of Henlius’s PD-L1 antibody-drug conjugate HLX43 with bevacizumab, with or without chemotherapy.
• The study targets advanced or metastatic solid tumors; the company plans to initiate trials once conditions are met.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260731-12263539), on July 31, 2026, and is solely responsible for the information contained therein.